Eton Pharmaceuticals：FDA批准DESMODA（去氨加压素）口服溶液

FDA于2026年2月25日批准了DESMODA（醋酸去氨加压素）口服溶液的NDA。该批准涵盖所有年龄段患者的中枢性尿崩症/AVP-D的抗利尿替代疗法。该产品现已获准在美国商业上市。

关键事实

申报时间: 2026年2月25日 19:18
事件: FDA 批准
方向: 积极
公司: ETONEton Pharmaceuticals
资产: desmopressin acetate
来源: SEC 8-K
可信度: 有来源

来源摘录

eton20260223_8k.htm false 0001710340 0001710340 2026-02-25 2026-02-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 February 25, 2026 Date of Report (Date of earliest event reported) ETON PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-38738 37-1858472 (State of (Commission (I.R.S. Employer incorporation) File Number) Identification Number) 21925 W. Field Parkway, Suite 235 Deer Park , Illinois 60010 -7278 (Address of principal executive offices) (Zip code) ( 847 ) 787-7361 (Registrant ’ s telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simul

SEC 8-K